Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ImnovAth

Financiado

Targeting the Imidazoline I1 receptor as a novel treatment for Atherosclerosis

Atherosclerosis (AT) is one of the main causes of death worldwide. Current treatments (e.g. lipid-lowering therapies) are still insufficient to tackle future CV events and we urgently need new complementary treatments to improve t... ver más

28/02/2026

CENTRO NACIONAL DE...

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASC... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 28M€

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-03-08

ERC-2023-POC: ERC PROOF OF CONCEPT GRANTS Objective:Objectives:The ERC Proof of Concept Grants aim at facilitating exploration of the commerci...

I+D

Cerrada hace 1 año

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

CENTRO NACIONAL DE INVESTIGA...

150.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAF2014-57845-R MODULACION INMUNOFARMACOLOGICA DE LA INFLAMACION SISTEMICA A... 303K€ Cerrado

SAF2017-82436-R MODULACION INMUNOMETABOLICA DEL MACROFAGO A TRAVES DE MTOR Y... 303K€ Cerrado

AGL2015-73744-JIN ESTUDIO METABOLOMICO DEL EFECTO MODULADOR DE LOS POLIFENOLES... 187K€ Cerrado

PRE2018-084351 MODULACION INMUNOMETABOLICA DEL MACROFAGO A TRAVES DE MTOR Y... 93K€ Cerrado

FJC2021-046455-I Vascular and immune cells crosstalk in metabolic syndrome: M... 65K€ Cerrado

FJC2021-048099-I Gut microbiota-derived metabolites in atherosclerosis diagno... 65K€ Cerrado

Duración del proyecto: 23 meses Fecha Inicio: 2024-03-08
Fecha Fin: 2026-02-28

Líder del proyecto

CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASC... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 28M€

Presupuesto del proyecto 150K€

Descripción del proyecto Atherosclerosis (AT) is one of the main causes of death worldwide. Current treatments (e.g. lipid-lowering therapies) are still insufficient to tackle future CV events and we urgently need new complementary treatments to improve therapeutic efficacy. ImnovAth aims to develop the new idea of targeting a metabolite/metabolite receptor axis to complete our preclinical results with an existing pharmacological agent that blocks this pathway, with the long-term goal of moving towards clinical trials and to a marketable product. In the context of our ERC-funded project, we found a microbiota-derived metabolite that affects the development of innate and adaptive immunity. We have subsequently found that this metabolite is both associated with and causal for AT and that blockade of the sensing of this metabolite prevents AT progression. We propose: 1) Validation to demonstrate that blockade of the metabolite/metabolite receptor axis is effective in AT treatment. We will study toxicity/tolerability of the existing pharmacological agent and the effect/efficacy of the blockade of this axis with the pharmacological agent alone or in combination with other current gold-standard treatments for AT in a preclinical therapeutic setting. 2) We will reinforce our IPR position and strategy proceeding towards a marketable product based on our currently filed patent application, market analysis and industry sector contacts. 3) Dissemination and communication activities. In sum, we propose an alternative therapy for AT focused on the inhibition of a novel target that can generate an independent or a complementary therapy to existing gold-standard treatments for AT, thus increasing their effectiveness.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores